Forte Biosciences Stock Price To Earnings To Growth

FBRX Stock

USD 16.08 0.08 0.50%

Forte Biosciences fundamentals help investors to digest information that contributes to Forte Biosciences' financial success or failures. It also enables traders to predict the movement of Forte Stock. The fundamental analysis module provides a way to measure Forte Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Forte Biosciences stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Forte Biosciences Company Price To Earnings To Growth Analysis

Forte Biosciences' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.

PEG Ratio

PE Ratio

EPS Growth

More About Price To Earnings To Growth | All Equity Analysis

Forte Price To Earnings To Growth Driver Correlations

Understanding the fundamental principles of building solid financial models for Forte Biosciences is extremely important. It helps to project a fair market value of Forte Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Forte Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Forte Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Forte Biosciences' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Short Term Investments	Long Term Debt Total	Capital Surpluse	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Short Term Debt	Net Tangible Assets	Net Invested Capital	Capital Stock	Net Working Capital	Deferred Long Term Liab
Total Assets		0.83	-0.06	-0.74	0.57	-0.38	0.83	-0.38	-0.15	0.6	1.0	0.24	0.7	0.61	-0.1	-0.24	-0.28	-0.35	-0.26	0.38
Total Stockholder Equity	0.83		-0.49	-0.53	0.24	-0.22	0.54	-0.22	0.17	0.06	0.85	0.51	0.35	0.17	-0.17	0.25	0.23	0.08	0.24	-0.01
Net Debt	-0.06	-0.49		-0.06	0.04	-0.4	0.42	-0.4	-0.79	0.6	-0.08	-0.26	0.04	0.69	0.47	-0.82	-0.83	-0.53	-0.83	0.5
Retained Earnings	-0.74	-0.53	-0.06		-0.73	0.32	-0.53	0.32	0.0	-0.57	-0.73	-0.47	-0.77	-0.49	0.34	0.21	0.24	0.05	0.24	-0.04
Accounts Payable	0.57	0.24	0.04	-0.73		0.0	0.32	0.0	0.22	0.7	0.55	0.09	0.96	0.33	-0.59	-0.35	-0.36	-0.27	-0.35	0.32
Long Term Debt	-0.38	-0.22	-0.4	0.32	0.0		-0.56	1.0	0.58	-0.38	-0.39	0.14	-0.03	-0.68	-0.62	0.58	0.55	0.57	0.54	-0.51
Short Term Investments	0.83	0.54	0.42	-0.53	0.32	-0.56		-0.56	-0.61	0.72	0.83	0.07	0.48	0.87	0.29	-0.61	-0.63	-0.6	-0.62	0.55
Long Term Debt Total	-0.38	-0.22	-0.4	0.32	0.0	1.0	-0.56		0.58	-0.38	-0.39	0.14	-0.03	-0.68	-0.62	0.58	0.55	0.57	0.54	-0.51
Capital Surpluse	-0.15	0.17	-0.79	0.0	0.22	0.58	-0.61	0.58		-0.51	-0.13	0.33	0.11	-0.78	-0.71	0.65	0.65	0.63	0.64	-0.58
Total Liab	0.6	0.06	0.6	-0.57	0.7	-0.38	0.72	-0.38	-0.51		0.57	-0.28	0.77	0.87	0.05	-0.81	-0.83	-0.75	-0.83	0.71
Total Current Assets	1.0	0.85	-0.08	-0.73	0.55	-0.39	0.83	-0.39	-0.13	0.57		0.25	0.68	0.6	-0.08	-0.23	-0.26	-0.34	-0.25	0.37
Common Stock	0.24	0.51	-0.26	-0.47	0.09	0.14	0.07	0.14	0.33	-0.28	0.25		0.07	-0.23	-0.45	0.43	0.43	0.68	0.41	-0.59
Property Plant Equipment	0.7	0.35	0.04	-0.77	0.96	-0.03	0.48	-0.03	0.11	0.77	0.68	0.07		0.44	-0.54	-0.37	-0.38	-0.35	-0.38	0.33
Current Deferred Revenue	0.61	0.17	0.69	-0.49	0.33	-0.68	0.87	-0.68	-0.78	0.87	0.6	-0.23	0.44		0.47	-0.81	-0.84	-0.74	-0.83	0.71
Short Term Debt	-0.1	-0.17	0.47	0.34	-0.59	-0.62	0.29	-0.62	-0.71	0.05	-0.08	-0.45	-0.54	0.47		-0.39	-0.41	-0.41	-0.41	0.38
Net Tangible Assets	-0.24	0.25	-0.82	0.21	-0.35	0.58	-0.61	0.58	0.65	-0.81	-0.23	0.43	-0.37	-0.81	-0.39		0.99	0.84	0.98	-0.72
Net Invested Capital	-0.28	0.23	-0.83	0.24	-0.36	0.55	-0.63	0.55	0.65	-0.83	-0.26	0.43	-0.38	-0.84	-0.41	0.99		0.81	1.0	-0.71
Capital Stock	-0.35	0.08	-0.53	0.05	-0.27	0.57	-0.6	0.57	0.63	-0.75	-0.34	0.68	-0.35	-0.74	-0.41	0.84	0.81		0.78	-0.89
Net Working Capital	-0.26	0.24	-0.83	0.24	-0.35	0.54	-0.62	0.54	0.64	-0.83	-0.25	0.41	-0.38	-0.83	-0.41	0.98	1.0	0.78		-0.68
Deferred Long Term Liab	0.38	-0.01	0.5	-0.04	0.32	-0.51	0.55	-0.51	-0.58	0.71	0.37	-0.59	0.33	0.71	0.38	-0.72	-0.71	-0.89	-0.68

Click cells to compare fundamentals

Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.

Competition

Predict Forte Biosciences

Forte Price Earnings To Growth Ratio

Price Earnings To Growth Ratio

(0.0315)

At this time, Forte Biosciences' Price Earnings To Growth Ratio is fairly stable compared to the past year.

Based on the latest financial disclosure, Forte Biosciences has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.

Forte Price To Earnings To Growth Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Forte Biosciences' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Forte Biosciences could also be used in its relative valuation, which is a method of valuing Forte Biosciences by comparing valuation metrics of similar companies.

Forte Biosciences is currently under evaluation in price to earnings to growth category among its peers.

Forte Biosciences ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Forte Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Forte Biosciences' managers, analysts, and investors.

Environmental

Governance

Social

Forte Fundamentals

	Return On Equity	-1.71
	Return On Asset	-0.81
	Current Valuation	7.03 M
	Shares Outstanding	1.46 M
	Shares Owned By Insiders	10.94 %
	Shares Owned By Institutions	54.05 %
	Number Of Shares Shorted	982
	Price To Book	2.50 X
	EBITDA	(32.48 M)
	Net Income	(31.48 M)
	Cash And Equivalents	38.55 M
	Cash Per Share	1.89 X
	Total Debt	3.67 M
	Current Ratio	25.67 X
	Book Value Per Share	24.30 X
	Cash Flow From Operations	(28.71 M)
	Short Ratio	0.09 X
	Earnings Per Share	(16.38) X
	Target Price	107.0
	Number Of Employees	11
	Beta	1.46
	Market Capitalization	23.39 M
	Total Asset	38.98 M
	Retained Earnings	(118.52 M)
	Working Capital	34.66 M
	Net Asset	38.98 M

About Forte Biosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Forte Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Forte Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Forte Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Forte Stock Analysis

When running Forte Biosciences' price analysis, check to measure Forte Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Forte Biosciences is operating at the current time. Most of Forte Biosciences' value examination focuses on studying past and present price action to predict the probability of Forte Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Forte Biosciences' price. Additionally, you may evaluate how the addition of Forte Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC